Buying and Selling Medtech | GenomeWeb

The US life sciences sector saw a flurry of merger and acquisition activity at the end of 2013, and it may continue into early 2014, according to an analysis from PricewaterhouseCoopers.

Overall, 2013 saw a contraction of 13 percent in medtech sector M&A, with a total of 41 deals, but a surge of 15 deals worth a collective $4.77 billion in the fourth quarter "may signal a healthy turn for the industry," MassDevice reports.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In the Soil

Califf Confirmed

Diversity Needed

This Week in PNAS

BGI Pursues IPO

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.